investors.merck.com Open in urlscan Pro
69.172.200.241 Public Scan

Go To Rescan
Add Verdict Report

URL:
https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Sur...
Submission: On October 24 via api (October 24th 2018, 12:13:29 pm UTC) from CH

Summary HTTP 52 Redirects Links 139 Behaviour Indicators

Summary

This website contacted 14 IPs in 5 countries across 12 domains to perform 52 HTTP transactions. The main IP is 69.172.200.241, located in New York, United States and belongs to DOSARREST - Dosarrest Internet Security LTD, US. The main domain is investors.merck.com.
TLS certificate: Issued by COMODO RSA Organization Validation Se... on September 11th 2018. Valid for: a year.

This is the only time investors.merck.com was scanned on urlscan.io!

urlscan.io Verdict: No classification

Domain & IP information

	IP Address	AS Autonomous System
7	69.172.200.241 69.172.200.241	19324 (DOSARREST) (DOSARREST - Dosarrest Internet Security LTD)
26	185.172.148.132 185.172.148.132	44239 (PROINITY ...) (PROINITY PROINITY)
1	2a00:1450:400... 2a00:1450:4001:819::200a	15169 (GOOGLE) (GOOGLE - Google LLC)
1	146.20.91.139 146.20.91.139	27357 (RACKSPACE) (RACKSPACE - Rackspace Hosting)
5	23.43.125.145 23.43.125.145	20940 (AKAMAI-ASN1) (AKAMAI-ASN1)
1 1	204.8.173.180 204.8.173.180	30574 (BUSINESS-...) (BUSINESS-WIRE - Business Wire)
1	23.8.12.53 23.8.12.53	20940 (AKAMAI-ASN1) (AKAMAI-ASN1)
2	2a00:1450:400... 2a00:1450:4001:819::200e	15169 (GOOGLE) (GOOGLE - Google LLC)
1	52.216.163.69 52.216.163.69	16509 (AMAZON-02) (AMAZON-02 - Amazon.com)
1	52.207.5.158 52.207.5.158	14618 (AMAZON-AES) (AMAZON-AES - Amazon.com)
1	2.16.186.243 2.16.186.243	20940 (AKAMAI-ASN1) (AKAMAI-ASN1)
1 3	18.185.192.244 18.185.192.244	16509 (AMAZON-02) (AMAZON-02 - Amazon.com)
2	104.111.218.204 104.111.218.204	16625 (AKAMAI-AS) (AKAMAI-AS - Akamai Technologies)
1	151.101.2.110 151.101.2.110	54113 (FASTLY) (FASTLY - Fastly)
52	14

7 69.172.200.241 (New York, United States)

ASN19324 (DOSARREST - Dosarrest Internet Security LTD, US)

investors.merck.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

26 185.172.148.132 (Germany)

ASN44239 (PROINITY PROINITY, DE)

s21.q4cdn.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

1 2a00:1450:4001:819::200a (Ireland)

ASN15169 (GOOGLE - Google LLC, US)

fonts.googleapis.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

1 146.20.91.139 (San Antonio, United States)

ASN27357 (RACKSPACE - Rackspace Hosting, US)

q4widgets.q4web.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

5 23.43.125.145 (Amsterdam, Netherlands)

ASN20940 (AKAMAI-ASN1, US)
PTR: a23-43-125-145.deploy.static.akamaitechnologies.com

ws.sharethis.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

1 204.8.173.180 (San Francisco, United States) 1 redirects

ASN30574 (BUSINESS-WIRE - Business Wire, US)
PTR: webdmz4.scprod.businesswire.com

cts.businesswire.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

1 23.8.12.53 (Amsterdam, Netherlands)

ASN20940 (AKAMAI-ASN1, US)
PTR: a23-8-12-53.deploy.static.akamaitechnologies.com

www.businesswire.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

2 2a00:1450:4001:819::200e (Ireland)

ASN15169 (GOOGLE - Google LLC, US)

www.google-analytics.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

1 52.216.163.69 (Ashburn, United States)

ASN16509 (AMAZON-02 - Amazon.com, Inc., US)

s3.amazonaws.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

1 52.207.5.158 (Ashburn, United States)

ASN14618 (AMAZON-AES - Amazon.com, Inc., US)
PTR: ec2-52-207-5-158.compute-1.amazonaws.com

www.bugherd.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

1 2.16.186.243 (European Union)

ASN20940 (AKAMAI-ASN1, US)
PTR: a2-16-186-243.deploy.static.akamaitechnologies.com

c.sharethis.mgr.consensu.org	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

3 18.185.192.244 (Cambridge, United States) 1 redirects

ASN16509 (AMAZON-02 - Amazon.com, Inc., US)
PTR: ec2-18-185-192-244.eu-central-1.compute.amazonaws.com

l.sharethis.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

2 104.111.218.204 (Amsterdam, Netherlands)

ASN16625 (AKAMAI-AS - Akamai Technologies, Inc., US)
PTR: a104-111-218-204.deploy.static.akamaitechnologies.com

t.sharethis.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

1 151.101.2.110 (San Francisco, United States)

ASN54113 (FASTLY - Fastly, US)

js-agent.newrelic.com	Domain lookup VirusTotal SecurityTrails crt.sh Censys Domaintools

	Apex Domain Subdomains	Transfer
26	q4cdn.com s21.q4cdn.com	503 KB
10	sharethis.com 1 redirects ws.sharethis.com l.sharethis.com t.sharethis.com	43 KB
7	merck.com investors.merck.com	107 KB
2	google-analytics.com www.google-analytics.com	17 KB
2	businesswire.com 1 redirects cts.businesswire.com www.businesswire.com	785 B
1	newrelic.com js-agent.newrelic.com	13 KB
1	consensu.org c.sharethis.mgr.consensu.org
1	bugherd.com www.bugherd.com	545 B
1	amazonaws.com s3.amazonaws.com	18 KB
1	q4web.com q4widgets.q4web.com	13 KB
1	googleapis.com fonts.googleapis.com	824 B
0	nr-data.net Failed bam.nr-data.net Failed
52	12

	Domain	Requested by
26	s21.q4cdn.com	investors.merck.com s21.q4cdn.com
7	investors.merck.com	investors.merck.com
5	ws.sharethis.com	investors.merck.com
3	l.sharethis.com	1 redirects investors.merck.com
2	t.sharethis.com	investors.merck.com t.sharethis.com
2	www.google-analytics.com	investors.merck.com
1	js-agent.newrelic.com	investors.merck.com
1	c.sharethis.mgr.consensu.org	investors.merck.com
1	www.bugherd.com	investors.merck.com
1	s3.amazonaws.com	investors.merck.com
1	www.businesswire.com	investors.merck.com
1	cts.businesswire.com	1 redirects
1	q4widgets.q4web.com	investors.merck.com
1	fonts.googleapis.com	investors.merck.com
0	bam.nr-data.net Failed	investors.merck.com
52	15

This site contains links to these domains. Also see Links.

Domain
www.merck.com
www.msd.com
www.essentialaccessibility.com
www.msdresponsibility.com
www.mrknewsroom.com
www.merck.ca
www.mercknewsroom.com
clinicaltrials.gov
cts.businesswire.com
businesswire.com
www.businesswire.com
privacy.truste.com
www.facebook.com
twitter.com
www.linkedin.com
q4inc.com

Subject Issuer	Validity	Valid
investors.merck.com COMODO RSA Organization Validation Secure Server CA	`2018-09-11` - `2019-09-11`	a year	crt.sh
*.q4cdn.com DigiCert SHA2 Secure Server CA	`2015-11-23` - `2019-01-03`	3 years	crt.sh
*.googleapis.com Google Internet Authority G3	`2018-10-02` - `2018-12-25`	3 months	crt.sh
*.q4web.com DigiCert SHA2 Secure Server CA	`2016-10-26` - `2019-12-04`	3 years	crt.sh
*.sharethis.com DigiCert SHA2 Secure Server CA	`2018-02-14` - `2019-02-14`	a year	crt.sh
www.businesswire.com DigiCert ECC Secure Server CA	`2018-06-06` - `2019-06-06`	a year	crt.sh
*.google-analytics.com Google Internet Authority G3	`2018-10-02` - `2018-12-25`	3 months	crt.sh
s3.amazonaws.com DigiCert Baltimore CA-2 G2	`2018-08-02` - `2019-10-25`	a year	crt.sh
*.bugherd.com COMODO RSA Domain Validation Secure Server CA	`2018-04-16` - `2019-06-15`	a year	crt.sh
*.sharethis.mgr.consensu.org DigiCert ECC Secure Server CA	`2018-07-31` - `2019-07-31`	a year	crt.sh
pxcel.net GeoTrust RSA CA 2018	`2018-01-22` - `2019-02-21`	a year	crt.sh
f4.shared.global.fastly.net GlobalSign CloudSSL CA - SHA256 - G3	`2018-10-03` - `2019-04-14`	6 months	crt.sh

This page contains 5 frames:

Primary Page: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Frame ID: 4109953AA03D223C6FFF4840D138563C
Requests: 48 HTTP requests in this frame

Frame: https://c.sharethis.mgr.consensu.org/v1.0/cmp/portal.html
Frame ID: 6E0FB706A838300BC28D874C79097D1F
Requests: 1 HTTP requests in this frame

Frame: https://t.sharethis.com/1/d/t.dhj?rnd=1540383199473&cid=c010&dmn=investors.merck.com
Frame ID: 3FC7E7BDDC5A2564D2E0C5F079281123
Requests: 1 HTTP requests in this frame

Frame: https://t.sharethis.com/a/t_.htm?ver=0.200.7868&cid=c010
Frame ID: 14A91697C9782BA8BAC40396BDB6DADC
Requests: 1 HTTP requests in this frame

Frame: https://ws.sharethis.com/secure5x/index.html
Frame ID: 0DB586F0A194094EA2A318E845213E82
Requests: 1 HTTP requests in this frame

Screenshot
Live screenshot

Full Image

Detected technologies

Windows Server (Operating Systems) Expand

Overall confidence: 50%
Detected patterns

url /\.aspx(?:$|\?)/i

Microsoft ASP.NET (Web Frameworks) Expand

Overall confidence: 100%
Detected patterns

url /\.aspx(?:$|\?)/i

Nginx (Web Servers) Expand

Overall confidence: 100%
Detected patterns

headers server /nginx(?:\/([\d.]+))?/i

Mustache (JavaScript Frameworks) Expand

Overall confidence: 100%
Detected patterns

env /^Mustache$/i

IIS (Web Servers) Expand

Overall confidence: 50%
Detected patterns

url /\.aspx(?:$|\?)/i

Google Analytics (Analytics) Expand

Overall confidence: 100%
Detected patterns

script /google-analytics\.com\/(?:ga|urchin|(analytics))\.js/i
env /^gaGlobal$/i

New Relic (Analytics) Expand

Overall confidence: 100%
Detected patterns

env /^NREUM/i

jQuery (JavaScript Libraries) Expand

Overall confidence: 100%
Detected patterns

env /^jQuery$/i

Page Statistics

52
Requests

98 %
HTTPS

14 %
IPv6

12
Domains

15
Subdomains

14
IPs

5
Countries

715 kB
Transfer

1546 kB
Size

7
Cookies

139 Outgoing links

These are links going to different origins than the main page.

URL: http://www.merck.com/index.html

Search URL Search Domain Scan URL

URL: http://www.msd.com/contact/contacts.html
Title: Worldwide

Search URL Search Domain Scan URL

URL: https://www.merck.com/contact/index.html
Title: Contact Us

Search URL Search Domain Scan URL

URL: https://www.essentialaccessibility.com/merck/?utm_source=merckhomepage&utm_medium=iconlarge&utm_term=eachannelpage&utm_content=header&utm_campaign=merck
Title:

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/home.html
Title: ABOUT US

Search URL Search Domain Scan URL

URL: http://www.msdresponsibility.com/
Title: Corporate Responsibility

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/leadership/home.html
Title: Leadership

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/leadership/board-of-directors/home.html
Title: Board of Directors

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/leadership/executive-committee/home.html
Title: Executive Committee

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/our-work/index.html
Title: Our Work

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/our-work/amr.html
Title: Antimicrobial Resistance

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/our-work/diabetes.html
Title: Diabetes

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/our-work/hepatitis-c.html
Title: Hepatitis C

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/our-work/hiv.html
Title: HIV

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/our-work/oncology.html
Title: Oncology

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/our-work/vaccine.html
Title: Vaccines

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/perspectives/home.html
Title: Perspectives

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/how-we-operate/home.html
Title: How We Operate

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/how-we-operate/code-of-conduct/home.html
Title: Code of Conduct

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/how-we-operate/compliance/home.html
Title: Compliance

Search URL Search Domain Scan URL

URL: http://www.msd.com/privacy/
Title: Privacy

Search URL Search Domain Scan URL

URL: http://www.msd.com/about/how-we-operate/privacy/transparency-and-privacy.html
Title: Transparency and Privacy

Search URL Search Domain Scan URL

URL: http://www.msd.com/privacy/internet-privacy-policy/
Title: Internet Privacy Policy

Search URL Search Domain Scan URL

URL: http://www.msd.com/privacy/cookie-privacy-commitment/
Title: Cookie Privacy Commitment

Search URL Search Domain Scan URL

URL: http://www.msd.com/privacy/cross-border-privacy-policy/
Title: Cross Border Policy

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/how-we-operate/privacy/employment-privacy-and-data-protection.html
Title: Employment Privacy & Data Protection

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/how-we-operate/diversity/home.html
Title: Diversity

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/how-we-operate/diversity/employee-diversity.html
Title: Employee Diversity

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/how-we-operate/diversity/programs-and-partnerships.html
Title: Programs and Partnerships

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/how-we-operate/diversity/supplier-diversity.html
Title: Supplier Diversity

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/views-and-positions/home.html
Title: Views and Positions

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/views-and-positions/access-and-affordability/home.html
Title: Access and Affordability

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/views-and-positions/access-to-medicines/home.html
Title: Access to Investigational Medicines

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/views-and-positions/innovation/home.html
Title: Innovation

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/views-and-positions/quality-and-safety/home.html
Title: Quality and Safety

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/views-and-positions/sales-and-marketing/home.html
Title: Sales and Marketing

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/views-and-positions/responsible-public-policy-and-advocacy/home.html
Title: Responsible Public Policy and Advocacy

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/our-history/home.html
Title: Our History

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/our-people/index.html
Title: Our People

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/featured-stories/home.html
Title: Featured Stories

Search URL Search Domain Scan URL

URL: https://www.merck.com/inventing-for-life/home.html
Title: Inventing For Life

Search URL Search Domain Scan URL

URL: https://www.merck.com/product/overview.html
Title: PRODUCTS

Search URL Search Domain Scan URL

URL: https://www.merck.com/product/home.html
Title: Product List A-Z

Search URL Search Domain Scan URL

URL: https://www.merck.com/product/vaccines/home.html
Title: Vaccines & Prescribing Information

Search URL Search Domain Scan URL

URL: https://www.merck.com/product/prescription-products/home.html
Title: Prescription Products & Prescribing Information

Search URL Search Domain Scan URL

URL: https://www.merck.com/product/oncology/home.html
Title: Oncology Products & Prescribing Information

Search URL Search Domain Scan URL

URL: https://www.merck.com/product/animal-health/home.html
Title: Animal Health

Search URL Search Domain Scan URL

URL: https://www.merck.com/product/access-and-patient-assistance.html
Title: Access and Patient Assistance

Search URL Search Domain Scan URL

URL: https://www.merck.com/product/patent/home.html
Title: Product Patents

Search URL Search Domain Scan URL

URL: https://www.merck.com/product/distributors/home.html
Title: Authorized Distributors

Search URL Search Domain Scan URL

URL: https://www.merck.com/product/safety-data/home.html
Title: Safety Data Sheets (SDS)

Search URL Search Domain Scan URL

URL: https://www.merck.com/research/index.html
Title: RESEARCH

Search URL Search Domain Scan URL

URL: https://www.merck.com/research/index.html#OurPeopleOurCulture
Title: Our People, Our Culture

Search URL Search Domain Scan URL

URL: https://www.merck.com/research/fellow/home.html
Title: The MRL Postdoctoral Fellow Program

Search URL Search Domain Scan URL

URL: https://www.merck.com/research/index.html#OurRDProcess
Title: Our R&D Process

Search URL Search Domain Scan URL

URL: https://www.merck.com/research/index.html#WhatWereWorkingOn
Title: What We're Working On

Search URL Search Domain Scan URL

URL: https://www.merck.com/research/index.html#Pipeline
Title: Pipeline

Search URL Search Domain Scan URL

URL: https://www.merck.com/research/index.html#ClinicalTrials
Title: Clinical Trials

Search URL Search Domain Scan URL

URL: https://www.merck.com/research/index.html#InventWithUs
Title: Invent with Us

Search URL Search Domain Scan URL

URL: https://www.merck.com/research/mrl-labs.html
Title: Discover Where Our Research Happens

Search URL Search Domain Scan URL

URL: https://www.merck.com/licensing/home.html
Title: LICENSING

Search URL Search Domain Scan URL

URL: https://www.merck.com/licensing/contact-us/home.html
Title: BD&L Contacts

Search URL Search Domain Scan URL

URL: https://www.merck.com/licensing/news-and-events/home.html
Title: News & Events

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/
Title: NEWSROOM

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/news-releases/all/all/all
Title: News Releases

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/news-releases/prescription-medicine-news
Title: Prescription Medicine News

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/news-releases/consumer_care_news
Title: Consumer Care News

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/news-releases/vaccine-news
Title: Vaccine News

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/news-releases/research-development-news
Title: Research & Development News

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/news-releases/corporate_news
Title: Corporate News

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/news-releases/financial-news
Title: Financial News

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/news-releases/corporate-responsibility-news
Title: Corporate Responsibility News

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/news-releases/animal_health_news
Title: Animal Health News

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/diabetes-infocenter
Title: Diabetes

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/ebola-infocenter
Title: Ebola

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/hepatitis_c-infocenter
Title: Hepatitis C

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/oncology-infocenter
Title: Oncology

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/company-statements/all/all/Company-Statements
Title: Company Statements

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/#MediaCenter
Title: Media Center

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/#CompanySnapshot
Title: Company Snapshot

Search URL Search Domain Scan URL

URL: https://www.mrknewsroom.com/#SocialMedia
Title: Social Media

Search URL Search Domain Scan URL

URL: https://www.merck.com/careers/home.html
Title: CAREERS

Search URL Search Domain Scan URL

URL: https://www.merck.com/careers/apply-now.html
Title: Apply Now

Search URL Search Domain Scan URL

URL: https://www.merck.com/careers/whats-possible.html
Title: What’s Possible?

Search URL Search Domain Scan URL

URL: https://www.merck.com/careers/why-merck.html
Title: Why Merck?

Search URL Search Domain Scan URL

URL: https://www.merck.com/careers/diversity-at-merck.html
Title: Diversity At Merck

Search URL Search Domain Scan URL

URL: https://www.merck.com/careers/from-service-to-science.html
Title: From Service to Science

Search URL Search Domain Scan URL

URL: https://www.merck.com/careers/life-at-merck/prepared-to-launch.html
Title: Student Opportunities

Search URL Search Domain Scan URL

URL: https://www.merck.com/careers/life-at-merck/benefits.html
Title: Compensation and Benefits

Search URL Search Domain Scan URL

URL: https://www.merck.com/careers/mmd-leadership.html
Title: MMD Leadership Program

Search URL Search Domain Scan URL

URL: https://www.merck.ca/English/careers/Pages/Home.aspx
Title: Canada

Search URL Search Domain Scan URL

URL: https://www.msd.com/careers/
Title: MSD Worldwide

Search URL Search Domain Scan URL

URL: http://www.merck.com/
Title: Home

Search URL Search Domain Scan URL

URL: https://www.merck.com/about/reimbursement-support-and-patient-assistance-programs/home.html
Title: Reimbursement Support and Patient Assistance Programs

Search URL Search Domain Scan URL

URL: http://www.msd.com/careers/en/index.html
Title: MSD Worldwide

Search URL Search Domain Scan URL

URL: http://www.merck.com/research/index.html#Pipeline
Title: Product Pipeline

Search URL Search Domain Scan URL

URL: http://www.mrknewsroom.com/
Title: News

Search URL Search Domain Scan URL

URL: http://www.merck.com/about/leadership/home.html
Title: Leadership & Governance

Search URL Search Domain Scan URL

URL: http://www.merck.com/about/leadership/executive-committee/home.html
Title: Executive Committee

Search URL Search Domain Scan URL

URL: http://www.merck.com/about/leadership/board-of-directors/home.html
Title: Board of Directors

Search URL Search Domain Scan URL

URL: https://www.merck.com/newsroom/
Title: Newsroom

Search URL Search Domain Scan URL

URL: https://www.merck.com/newsroom/#News
Title: News Releases

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/news-releases/prescription-medicine-news
Title: Prescription Medicine News

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/news-releases/consumer_care_news
Title: Consumer Care News

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/news-releases/vaccine-news
Title: Vaccine News

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/news-releases/research-development-news
Title: Research & Development News

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/news-releases/corporate_news
Title: Corporate News

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/news-releases/financial-news
Title: Financial News

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/news-releases/corporate-responsibility-news
Title: Corporate Responsibility News

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/news-releases/animal_health_news
Title: Animal Health News

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/ebola-infocenter
Title: Ebola

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/hepatitis_c-infocenter
Title: Hepatitis C

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/oncology-infocenter
Title: Oncology

Search URL Search Domain Scan URL

URL: https://www.mercknewsroom.com/company-statements/all/all/Company-Statements
Title: Company Statements

Search URL Search Domain Scan URL

URL: https://www.merck.com/newsroom/#MediaCenter
Title: Media Center

Search URL Search Domain Scan URL

URL: https://www.merck.com/newsroom/#CompanySnapshot
Title: Company Snapshot

Search URL Search Domain Scan URL

URL: https://www.merck.com/newsroom/#SocialMedia
Title: Social Media

Search URL Search Domain Scan URL

URL: https://www.merck.com/contact/contact-faq.html
Title: FAQ

Search URL Search Domain Scan URL

URL: http://clinicaltrials.gov/
Title: ClinicalTrials.gov

Search URL Search Domain Scan URL

URL: http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.merck.com%2Fclinicaltrials&esheet=51886428&newsitemid=20181022005244&lan=en-US&anchor=www.merck.com%2Fclinicaltrials&index=1&md5=bd80e6e981bbb5a5d38bbe2e91f42c4f
Title: www.merck.com/clinicaltrials

Search URL Search Domain Scan URL

URL: http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.merck.com&esheet=51886428&newsitemid=20181022005244&lan=en-US&anchor=www.merck.com&index=2&md5=429a45d96c9c44e9fe7e93703c29735b
Title: www.merck.com

Search URL Search Domain Scan URL

URL: http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Ftwitter.com%2FMerck&esheet=51886428&newsitemid=20181022005244&lan=en-US&anchor=Twitter&index=3&md5=9d7ccf26cce2bc89b293ca4582cdbec0
Title: Twitter

Search URL Search Domain Scan URL

URL: http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.facebook.com%2FMerckInvents%2F&esheet=51886428&newsitemid=20181022005244&lan=en-US&anchor=Facebook&index=4&md5=bdd813515d1ac68bb8f9f516e33bbc8d
Title: Facebook

Search URL Search Domain Scan URL

URL: http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.instagram.com%2Fmerck%2F&esheet=51886428&newsitemid=20181022005244&lan=en-US&anchor=Instagram&index=5&md5=e7708dfb1886950b974f62085e07c3e4
Title: Instagram

Search URL Search Domain Scan URL

URL: http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&esheet=51886428&newsitemid=20181022005244&lan=en-US&anchor=YouTube&index=6&md5=89db2fbc0e6fc82b674b8db8ff0f73e7
Title: YouTube

Search URL Search Domain Scan URL

URL: http://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&esheet=51886428&newsitemid=20181022005244&lan=en-US&anchor=LinkedIn&index=7&md5=1f1948b91610712dd541ff677350aab0
Title: LinkedIn

Search URL Search Domain Scan URL

URL: http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.sec.gov%2F&esheet=51886428&newsitemid=20181022005244&lan=en-US&anchor=www.sec.gov&index=8&md5=58c67c790f3447177818bbbc197c2bfe
Title: www.sec.gov

Search URL Search Domain Scan URL

URL: http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&esheet=51886428&newsitemid=20181022005244&lan=en-US&anchor=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&index=9&md5=57ed4f7cf8198f19161e128c454d41a4
Title: http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf

Search URL Search Domain Scan URL

URL: http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&esheet=51886428&newsitemid=20181022005244&lan=en-US&anchor=http%3A%2F%2Fwww.merck.com%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&index=10&md5=09749aef064aea0bb757c005d19a9164
Title: http://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_mg.pdf

Search URL Search Domain Scan URL

URL: http://businesswire.com/
Title: businesswire.com

Search URL Search Domain Scan URL

URL: https://www.businesswire.com/news/home/20181022005244/en/
Title: https://www.businesswire.com/news/home/20181022005244/en/

Search URL Search Domain Scan URL

URL: http://www.merck.com/policy/copyright/home.html
Title: Copyright

Search URL Search Domain Scan URL

URL: https://www.merck.com/policy/terms-of-use/home.html
Title: Terms of Use

Search URL Search Domain Scan URL

URL: https://www.merck.com/map/home.html
Title: Site Map

Search URL Search Domain Scan URL

URL: http://privacy.truste.com/privacy-seal/Merck-and-Co-,-Inc-/validation?rid=7437b42b-c947-434e-b1f5-db06d0327616
Title:

Search URL Search Domain Scan URL

URL: https://www.facebook.com/MerckBeWell
Title:

Search URL Search Domain Scan URL

URL: https://twitter.com/merck
Title:

Search URL Search Domain Scan URL

URL: https://www.linkedin.com/company/merck
Title:

Search URL Search Domain Scan URL

URL: http://q4inc.com/Powered-by-Q4/
Title: Powered By Q4 Inc. 5.14.0.4 (opens in new window)

Search URL Search Domain Scan URL

Redirected requests

There were HTTP redirect chains for the following requests:

Request Chain 18

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20181022005244r1&sid=acqr7&distro=nx&lang=en HTTP 301
https://www.businesswire.com/images/spacer.gif

Request Chain 42

https://l.sharethis.com/pview?event=pview&version=buttons.js&lang=en&fpc=d13c64-166a5fe4fb6-13f73f01-1&sessionID=1540383199158.59352&hostname=investors.merck.com&location=%2Fnews%2Fpress-release-details%2F2018%2FMercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer%2Fdefault.aspx&product=widget&stid=&publisher=0b1768c0-8292-4405-a3c3-08c8afe66a3c&st_optout=false&refDomain=&refQuery=&url=https%3A%2F%2Finvestors.merck.com%2Fnews%2Fpress-release-details%2F2018%2FMercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer%2Fdefault.aspx&sharURL=&buttonType=ERROR&destination=ERROR&source=ERROR&title=Merck%20%26%20Co.%2C%20Inc.%20-%20Merck%E2%80%99s%20KEYTRUDA%20(pembrolizumab)%20Significantly%20Improved%20Overall%20Survival%20Compared%20to%20Standard%20of%20Care%2C%20as%20Monotherapy%20and%20in%20Combination%20with%20Chemotherapy%2C%20as%20First-Line%20Treatment%20for%20Patients%20with%20Recurrent%20or%20Metastatic%20Head%20and%20Neck%20Cancer&ts1540383199159.0=&sop=false HTTP 301
https://l.sharethis.com/sc?cm=ZGAUr1vQYd8AAAAUG%2FBcAw%3D%3D&uid=true&url=https%3A%2F%2Finvestors.merck.com%2Fnews%2Fpress-release-details%2F2018%2FMercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer%2Fdefault.aspx

52 HTTP transactions
0 data transactions

Method
Protocol Status Resource
Path Size
x-fer Time
Latency Type
MIME-Type IP
Location

GET
H/1.1 200
OK Primary Request default.aspx Show response
investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemoth... 181 KB
46 KB 486ms
206ms Document
text/html 69.172.200.241
Dosarrest Interne...

General

Check archive.org

Show headers Download Go to

Full URL

https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx

Protocol

HTTP/1.1

Security

TLS 1.2, ECDHE_RSA, AES_256_GCM

Server

69.172.200.241 New York, United States, ASN19324 (DOSARREST - Dosarrest Internet Security LTD, US),

Reverse DNS

Software

nginx /

Resource Hash

85311fc02c8b33df9eb7186c78288d6ad37f44b98ce10499b126a517523782a1

Security Headers

Name	Value
Strict-Transport-Security	max-age=3600

Request headers

Host: investors.merck.com
Connection: keep-alive
Pragma: no-cache
Cache-Control: no-cache
Upgrade-Insecure-Requests: 1
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Accept: text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8
Accept-Encoding: gzip, deflate
Upgrade-Insecure-Requests: 1
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Server: nginx
Date: Wed, 24 Oct 2018 12:13:18 GMT
Content-Type: text/html; charset=utf-8
Transfer-Encoding: chunked
Connection: keep-alive
Cache-Control: public, max-age=10
Strict-Transport-Security: max-age=3600
X-Cache-status: REVALIDATED
X-Edge-Location: q4web-prod-contentcache-us-east-1-i-032eb105ed8ce7e3c
Content-Encoding: gzip

GET
H/1.1 200
OK mobileRedirect.js Show response
investors.merck.com/js/ 3 KB
3 KB 465ms
274ms Script
application/javascript 69.172.200.241
Dosarrest Interne...

General

Check archive.org

Show headers Download Go to

Full URL

https://investors.merck.com/js/mobileRedirect.js

Requested by

Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx

Protocol

HTTP/1.1

Security

TLS 1.2, ECDHE_RSA, AES_256_GCM

Server

69.172.200.241 New York, United States, ASN19324 (DOSARREST - Dosarrest Internet Security LTD, US),

Reverse DNS

Software

nginx /

Resource Hash

b98d351ce03836792ec6dcea20126eed347a26760525ca4d9fa4dc0e6b1b758c

Security Headers

Name	Value
Strict-Transport-Security	max-age=3600

Request headers

Pragma: no-cache
Accept-Encoding: gzip, deflate
Host: investors.merck.com
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Accept: */*
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Connection: keep-alive
Cache-Control: no-cache
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:18 GMT
Last-Modified: Fri, 19 Oct 2018 18:27:42 GMT
Server: nginx
X-Edge-Location: q4web-prod-contentcache-us-east-1-i-032eb105ed8ce7e3c
ETag: bb63ab5e9377998a87d776a08b5759a1
X-Cache-status: HIT
Strict-Transport-Security: max-age=3600
Content-Type: application/javascript
Cache-Control: public, max-age=10
Connection: keep-alive
Accept-Ranges: bytes
Content-Length: 2923

GET
S 200 jquery-ui.css
s21.q4cdn.com/488056881/files/css/ 35 KB
10 KB 61ms
7ms Stylesheet
text/css 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/css/jquery-ui.css
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 36bd3cb6e3dda2c43f9be760d6ac82bc80346ec9576419d0941aaf42d0499a13

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
content-encoding: gzip
last-modified: Wed, 01 Mar 2017 07:23:20 GMT
server: keycdn-engine
x-amz-request-id: 2A7BC65E12C16D20
x-edge-location: defr
etag: W/"76e9acfcf50d527a9256546ad635da74"
vary: Accept-Encoding
x-cache: HIT
content-type: text/css
status: 200
cache-control: max-age=3600
access-control-allow-origin: *
x-amz-id-2: +Xly6iKNizNBnZLbiFh+HIpUHHEPXu3oyi9bOtIOpkKLkFfnPkRfRL4U/uR50jF4tSDauMe2zyo=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 css
fonts.googleapis.com/ 7 KB
824 B 19ms
17ms Stylesheet
text/css 2a00:1450:4001:819::200a
Google LLC

General

Check archive.org

Show headers Download Go to

Full URL

https://fonts.googleapis.com/css?family=Open+Sans:400,300,600

Requested by

Protocol

SPDY

Security

TLS 1.2, ECDHE_ECDSA, AES_128_GCM

Server

2a00:1450:4001:819::200a , Ireland, ASN15169 (GOOGLE - Google LLC, US),

Reverse DNS

Software

ESF /

Resource Hash

b3d14d1b50ce79edbcdede2f1fe0f39e34a0d531d8e8b0b6c9dd9eb9d81c1ba6

Security Headers

Name	Value
Strict-Transport-Security	max-age=604800
X-Frame-Options	SAMEORIGIN
X-Xss-Protection	1; mode=block

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

strict-transport-security: max-age=604800
content-encoding: gzip
last-modified: Wed, 24 Oct 2018 12:13:18 GMT
server: ESF
link: <https://fonts.gstatic.com>; rel=preconnect; crossorigin
status: 200
date: Wed, 24 Oct 2018 12:13:18 GMT
x-frame-options: SAMEORIGIN
content-type: text/css; charset=utf-8
access-control-allow-origin: *
cache-control: private, max-age=86400, stale-while-revalidate=604800
timing-allow-origin: *
alt-svc: quic=":443"; ma=2592000; v="44,43,39,35"
x-xss-protection: 1; mode=block
expires: Wed, 24 Oct 2018 12:13:18 GMT

GET
H/1.1 200
OK default.css
investors.merck.com/css/ 889 B
1 KB 189ms
124ms Stylesheet
text/css 69.172.200.241
Dosarrest Interne...

General

Check archive.org

Show headers Download Go to

Full URL

https://investors.merck.com/css/default.css

Requested by

Protocol

HTTP/1.1

Security

TLS 1.2, ECDHE_RSA, AES_256_GCM

Server

69.172.200.241 New York, United States, ASN19324 (DOSARREST - Dosarrest Internet Security LTD, US),

Reverse DNS

Software

nginx /

Resource Hash

47a464671518b615b583a679e3779ecdb8a4668732cf00b06a4ad3d29ccc12d3

Security Headers

Name	Value
Strict-Transport-Security	max-age=3600

Request headers

Pragma: no-cache
Accept-Encoding: gzip, deflate
Host: investors.merck.com
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Accept: text/css,*/*;q=0.1
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Connection: keep-alive
Cache-Control: no-cache
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:18 GMT
Last-Modified: Fri, 19 Oct 2018 18:27:40 GMT
Server: nginx
X-Edge-Location: q4web-prod-contentcache-us-east-1-i-032eb105ed8ce7e3c
ETag: 5cc5310e7b31244c6daef5d47f93792a
X-Cache-status: REVALIDATED
Strict-Transport-Security: max-age=3600
Content-Type: text/css
Cache-Control: public, max-age=10
Connection: keep-alive
Accept-Ranges: bytes
Content-Length: 889

GET
S 200 global.css
s21.q4cdn.com/488056881/files/css/ 151 KB
33 KB 67ms
13ms Stylesheet
text/css 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/css/global.css?v=25127
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 20418f12b34115618d04a50dcb704bc34055ccb684932ac7d7c78477cae46e17

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
content-encoding: gzip
last-modified: Thu, 13 Sep 2018 14:26:59 GMT
server: keycdn-engine
x-amz-request-id: EA4917FDF686D78F
x-edge-location: defr
etag: W/"d0cc3cd1aed1b3b87cb6343ba3c7c903"
vary: Accept-Encoding
x-cache: HIT
content-type: text/css
status: 200
cache-control: max-age=3600
access-control-allow-origin: *
x-amz-id-2: h0QJBnjXAbnEeL+vjTsNyJQeQHsuvmuuYjj3VNpMq4JsY0jJiYz/5Zhw0QInsrfVnQxqgKKx5Hg=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 client.css
s21.q4cdn.com/488056881/files/css/ 14 KB
4 KB 66ms
12ms Stylesheet
text/css 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/css/client.css?v=23851
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 6df18cd6c41228369cf4c27272f00bdd8e740a665cb37ee579962692a20a4519

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
content-encoding: gzip
last-modified: Tue, 18 Apr 2017 14:00:19 GMT
server: keycdn-engine
x-amz-request-id: 43226DBC5026793F
x-edge-location: defr
etag: W/"1d583ae03757dc6695f796ed86986966"
vary: Accept-Encoding
x-cache: HIT
content-type: text/css
status: 200
cache-control: max-age=3600
access-control-allow-origin: *
x-amz-id-2: fxxSufMSa5V46z/bcyxuNvjW3uIgfcpyeLHPIhFlhTmCxu8/wa0e9bW1jT1vjujAt3zh5dKhvKs=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 q4.core.js Show response
s21.q4cdn.com/488056881/files/js/ 424 KB
148 KB 72ms
19ms Script
application/x-javascript 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/js/q4.core.js
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: d4dad8af91edb51fd0f1ad301a42755d8afd2ecb23d8bb3f4e6e4d67689f56bd

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
content-encoding: gzip
last-modified: Wed, 14 Dec 2016 17:40:36 GMT
server: keycdn-engine
x-amz-request-id: A777CFC12B76B20C
x-edge-location: defr
etag: W/"c07882c95424018700c47862e8a7614c"
vary: Accept-Encoding
x-cache: HIT
content-type: application/x-javascript
status: 200
cache-control: max-age=3600
access-control-allow-origin: *
x-amz-id-2: pw42p4PtAd7rWxzTb7PAy4D2Ux2mQCczqQ0+fsGg7K5bmqF8MZGa+GzZ8RO2nlAJQfITjjcyt2I=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 q4.app.js Show response
s21.q4cdn.com/488056881/files/js/ 9 KB
3 KB 72ms
18ms Script
application/x-javascript 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/js/q4.app.js
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: a9375a78e7e1fabbef24351a1d8c1430ad18324d3e42115411d302b3175516af

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
content-encoding: gzip
last-modified: Tue, 08 Nov 2016 14:50:10 GMT
server: keycdn-engine
x-amz-request-id: 7A52EED53E45BD7E
x-edge-location: defr
etag: W/"feef580cc0160cea9da2180243dd1943"
vary: Accept-Encoding
x-cache: HIT
content-type: application/x-javascript
status: 200
cache-control: max-age=3600
access-control-allow-origin: *
x-amz-id-2: U7O4Jy0dIW23utn1YnUsfeKVb6FaRll7qE1dnrlrZk/7pBzNNrB6PNCiB6Ix5YqBaN7psZ2x5Ko=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 icheck.min.js Show response
s21.q4cdn.com/488056881/files/js/ 5 KB
3 KB 71ms
18ms Script
application/x-javascript 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/js/icheck.min.js
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: f0718dd44766296547e2153766bdc56d31e8aac51c7ed78b6499d59aa0ffac2f

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
content-encoding: gzip
last-modified: Tue, 08 Nov 2016 12:29:38 GMT
server: keycdn-engine
x-amz-request-id: CE0E117A85AE4F07
x-edge-location: defr
etag: W/"b49273b51dae7361e02dca0763144e54"
vary: Accept-Encoding
x-cache: HIT
content-type: application/x-javascript
status: 200
cache-control: max-age=3600
access-control-allow-origin: *
x-amz-id-2: WXTC2iDq5nv/hFUQ3faGxVTOVJm6toKAy7zf+HsyNzoZd1VLahEwjch8Xk+9OyWRid+4n2jn2q0=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 hover-plugin.js Show response
s21.q4cdn.com/488056881/files/js/ 1 KB
927 B 76ms
23ms Script
application/x-javascript 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/js/hover-plugin.js
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: b5112e8b4fd9af839b8f12bb21502356c6d7ddc7c87a5f3c178723e12c6dab4d

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
content-encoding: gzip
last-modified: Tue, 29 Nov 2016 12:45:18 GMT
server: keycdn-engine
x-amz-request-id: 3DFB2C4F51C907F0
x-edge-location: defr
etag: W/"c747ba005e861823cfa1ff06fec94fb7"
vary: Accept-Encoding
x-cache: HIT
content-type: application/x-javascript
status: 200
cache-control: max-age=3600
access-control-allow-origin: *
x-amz-id-2: If2zie4DJ978fo2zXxqlxjG+1ifDBzmuZP2EUGPy+P4BucOQyl/BJDkvTI+HJW9Wy7xLgHbkH1Q=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
H/1.1 200
OK all.css
q4widgets.q4web.com/prDetails/css/ 101 KB
13 KB 533ms
200ms Stylesheet
text/css 146.20.91.139
Rackspace Hosting

General

Check archive.org

Show headers Download Go to

Full URL: https://q4widgets.q4web.com/prDetails/css/all.css
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: HTTP/1.1
Security: TLS 1.2, RSA, AES_256_GCM
Server: 146.20.91.139 San Antonio, United States, ASN27357 (RACKSPACE - Rackspace Hosting, US),
Reverse DNS
Software: Microsoft-IIS/8.5 / ASP.NET
Resource Hash: 740c5280464a5d483323797a2042ea3ed6b3988e792d44a69ffb4e7e2dfcd42d

Request headers

User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:18 GMT
Content-Encoding: gzip
Last-Modified: Tue, 17 Nov 2015 15:14:39 GMT
Server: Microsoft-IIS/8.5
X-Powered-By: ASP.NET
ETag: "805958ad4a21d11:0"
Vary: Accept-Encoding
Content-Type: text/css
Accept-Ranges: bytes
Content-Length: 13513

GET
H/1.1 200
OK WebResource.axd Show response
investors.merck.com/ 23 KB
23 KB 570ms
107ms Script
application/x-javascript 69.172.200.241
Dosarrest Interne...

General

Check archive.org

Show headers Download Go to

Full URL

https://investors.merck.com/WebResource.axd?d=pynGkmcFUV13He1Qd6_TZDSH1oVlXKNmZSXd3zYZ2Gq6ERm6jivSb4ijerOGYkuGRtePZg2&t=636576850476690871

Requested by

Protocol

HTTP/1.1

Security

TLS 1.2, ECDHE_RSA, AES_256_GCM

Server

69.172.200.241 New York, United States, ASN19324 (DOSARREST - Dosarrest Internet Security LTD, US),

Reverse DNS

Software

nginx /

Resource Hash

40732e9dcfa704cf615e4691bb07aecfd1cc5e063220a46e4a7ff6560c77f5db

Security Headers

Name	Value
Strict-Transport-Security	max-age=3600

Request headers

Pragma: no-cache
Accept-Encoding: gzip, deflate
Host: investors.merck.com
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Accept: */*
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Connection: keep-alive
Cache-Control: no-cache
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:18 GMT
Last-Modified: Mon, 26 Mar 2018 23:17:27 GMT
Server: nginx
X-Edge-Location: q4web-prod-contentcache-us-east-1-i-032eb105ed8ce7e3c
X-Cache-status: HIT
Strict-Transport-Security: max-age=3600
Content-Type: application/x-javascript
Cache-Control: public
Connection: keep-alive
Content-Length: 23063
Expires: Thu, 17 Oct 2019 22:23:35 GMT

GET
H/1.1 200
OK WebResource.axd Show response
investors.merck.com/ 26 KB
27 KB 652ms
179ms Script
application/x-javascript 69.172.200.241
Dosarrest Interne...

General

Check archive.org

Show headers Download Go to

Full URL: https://investors.merck.com/WebResource.axd?d=x2nkrMJGXkMELz33nwnakMh5buNcZ-t3T4nCU0ZQt96Kk4JDhdv7pdb3Agzis1zDln1EUlimtVH-8O9nKu6Z_e6vBso1&t=636576850476690871
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: HTTP/1.1
Security: TLS 1.2, ECDHE_RSA, AES_256_GCM
Server: 69.172.200.241 New York, United States, ASN19324 (DOSARREST - Dosarrest Internet Security LTD, US),
Reverse DNS
Software: nginx /
Resource Hash: ef9453f74b2617d43dcef4242cf5845101fcfb57289c81bceb20042b0023a192

Request headers

Pragma: no-cache
Accept-Encoding: gzip, deflate
Host: investors.merck.com
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Accept: */*
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Connection: keep-alive
Cache-Control: no-cache
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:18 GMT
Last-Modified: Mon, 28 Aug 2017 19:11:58 GMT
Server: nginx
X-Edge-Location: q4web-prod-contentcache-us-east-1-i-0bcdb9d69efdb25ce
X-Cache-status: HIT
Content-Type: application/x-javascript
Cache-Control: public
Connection: keep-alive
Content-Length: 26951
Expires: Thu, 17 Oct 2019 07:38:23 GMT

GET
S 200 mrk_ifl_lg_rgb_tl_dkgry.jpg
s21.q4cdn.com/488056881/files/design/logo/ 100 KB
100 KB 15ms
15ms Image
image/jpeg 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/logo/mrk_ifl_lg_rgb_tl_dkgry.jpg
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: c03e8e0e6c5126e7202c44aaf5286408416fc015720f9c179e5fe5ce1b59a461

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
last-modified: Tue, 11 Sep 2018 23:54:15 GMT
server: keycdn-engine
x-amz-request-id: 57ABE38C5A12517F
x-edge-location: defr
etag: "202e688ee9db5f73c2b63b02cef72a7e"
x-cache: HIT
content-type: image/jpeg
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 102360
x-amz-id-2: MQeEeE9+VGgJ2ZIhkGLeqsXi/5HWeBhd1RpdxEOzDGJuh2NsxszqENmu0hggyT4r35d5Kkb/amM=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 worldwide-green.png
s21.q4cdn.com/488056881/files/design/ 1 KB
2 KB 15ms
15ms Image
image/png 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/worldwide-green.png
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 04c213d5bacd6d0bc65b74d7e5f6d63a098b49bf127649c5f6f5d6838eb566af

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
last-modified: Tue, 18 Apr 2017 13:59:47 GMT
server: keycdn-engine
x-amz-request-id: 3746A8C22926AFC9
x-edge-location: defr
etag: "ac3053a43cefa8c8c1fc26169e1ac85e"
x-cache: HIT
content-type: image/png
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 1309
x-amz-id-2: dAlHD0b28ufAcH2KWqZM2nqbQcHOiS2jyu7dyEYF8MfDwFhiiURjDzQQQeNQVhOT73LQmgqxbSk=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 contact-green.png
s21.q4cdn.com/488056881/files/design/ 1 KB
2 KB 7ms
7ms Image
image/png 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/contact-green.png
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 0da40f201e733893f8560119f465cd03c19133c2770ba81960679d005ce39240

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
last-modified: Tue, 18 Apr 2017 13:59:53 GMT
server: keycdn-engine
x-amz-request-id: 4692D33F3783BEAA
x-edge-location: defr
etag: "bc2ae50d1a784111b4aac3f10223ac8a"
x-cache: HIT
content-type: image/png
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 1185
x-amz-id-2: EIv5MPC57itqxcMFptnYgs7r1q01R4Z+G4mBgsrpvr62MbFV5sOkeUZjsBCCvC+SDLYXDGKLCnc=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 ea_app_icon2.png
s21.q4cdn.com/488056881/files/design/ 6 KB
6 KB 6ms
5ms Image
image/png 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/ea_app_icon2.png
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 466bc7baea2120251d956311251838dfdbf6d27c9d3cf585540521c266f17ccb

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
last-modified: Tue, 18 Apr 2017 13:57:58 GMT
server: keycdn-engine
x-amz-request-id: DFE391650851E47F
x-edge-location: defr
etag: "7cfe2b54a16063c69eff1d9b7afe7b38"
x-cache: HIT
content-type: image/png
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 6274
x-amz-id-2: 0coLk1iOnxIEOgFtPLpSuiyE6/WNtcYbh7W0cvlO/TRB6rRIuv3Z3QlrX+ap6bW6SDvqxjtlTAI=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
H/1.1 200
OK buttons.js Show response
ws.sharethis.com/button/ 54 KB
15 KB 54ms
6ms Script
application/javascript 23.43.125.145
AKAMAI-ASN1

General

Check archive.org

Show headers Download Go to

Full URL: https://ws.sharethis.com/button/buttons.js
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: HTTP/1.1
Security: TLS 1.2, ECDHE_RSA, AES_256_GCM
Server: 23.43.125.145 Amsterdam, Netherlands, ASN20940 (AKAMAI-ASN1, US),
Reverse DNS: a23-43-125-145.deploy.static.akamaitechnologies.com
Software: nginx/1.12.2 /
Resource Hash: 1b00a109efa27819449f08da220246851dfc2948f485d92b31581a85a4db0150

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:18 GMT
Content-Encoding: gzip
Server: nginx/1.12.2
ETag: W/"5b96ef33-d9a9"
Vary: Accept-Encoding
Content-Type: application/javascript
Cache-Control: max-age=229451
Connection: keep-alive
Content-Length: 15380
Expires: Sat, 27 Oct 2018 03:57:29 GMT

GET
H/1.1

200
OK

spacer.gif
www.businesswire.com/images/
Redirect Chain

http://cts.businesswire.com/ct/CT?id=bwnews&sty=20181022005244r1&sid=acqr7&distro=nx&lang=en
https://www.businesswire.com/images/spacer.gif

43 B
418 B

58ms
8ms

Image
image/gif

23.8.12.53
AKAMAI-ASN1

General

Check archive.org

Show headers Download Go to Show image

Full URL

https://www.businesswire.com/images/spacer.gif

Requested by

Protocol

HTTP/1.1

Security

TLS 1.2, ECDHE_ECDSA, AES_256_GCM

Server

23.8.12.53 Amsterdam, Netherlands, ASN20940 (AKAMAI-ASN1, US),

Reverse DNS

a23-8-12-53.deploy.static.akamaitechnologies.com

Software

Apache /

Resource Hash

24e480e4659fbae818853a38f8a3036f529f539024dc3e772c0b594ce02ea9db

Security Headers

Name	Value
Strict-Transport-Security	max-age=31536000; includeSubDomains

Request headers

User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Strict-Transport-Security: max-age=31536000; includeSubDomains
Last-Modified: Tue, 14 Aug 2018 17:00:18 GMT
Server: Apache
ETag: "813e5-2b-5736824fe6c80"
Content-Type: image/gif
Cache-Control: max-age=11027
Date: Wed, 24 Oct 2018 12:13:19 GMT
Connection: keep-alive
Accept-Ranges: bytes
Content-Length: 43
Expires: Wed, 24 Oct 2018 15:17:06 GMT

Redirect headers

Location: https://www.businesswire.com/images/spacer.gif
Date: Wed, 24 Oct 2018 12:13:19 GMT
Server: Apache
Connection: Keep-Alive
Keep-Alive: timeout=15, max=100
Content-Length: 0
Content-Type: text/plain; charset=UTF-8

GET
S 200 mail-ico.png
s21.q4cdn.com/488056881/files/design/ 606 B
960 B 7ms
5ms Image
image/png 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/mail-ico.png
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 6853c44eb956622bb14dfcbd28b51532cad859fccac4d0e580585276718abf23

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
last-modified: Tue, 29 Nov 2016 08:44:51 GMT
server: keycdn-engine
x-amz-request-id: C0CD3FFECC1C2D3B
x-edge-location: defr
etag: "cbc09dfa7ab09236a0e8d6af98569b42"
x-cache: HIT
content-type: image/png
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 606
x-amz-id-2: az1EYUbzPslJTBsG/4Sr3Z7LmLoK1ioBES62l8D68cLOdMd7wBARf0xRiQfwHp5c/osGMSHqC2k=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
H/1.1 200
OK Cookie set captcha
investors.merck.com/q4api/v1/ 4 KB
4 KB 124ms
123ms Image
image/jpeg 69.172.200.241
Dosarrest Interne...

General

Check archive.org

Show headers Download Go to Show image

Full URL

https://investors.merck.com/q4api/v1/captcha?clientId=_ctrl0_ctl48_UCCaptcha

Requested by

Protocol

HTTP/1.1

Security

TLS 1.2, ECDHE_RSA, AES_256_GCM

Server

69.172.200.241 New York, United States, ASN19324 (DOSARREST - Dosarrest Internet Security LTD, US),

Reverse DNS

Software

nginx /

Resource Hash

df90f1a1f469a1d6d34656d36e0fd348896a38e8f4c14730bbe074869b296a3b

Security Headers

Name	Value
X-Frame-Options	DENY

Request headers

Pragma: no-cache
Accept-Encoding: gzip, deflate
Host: investors.merck.com
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Accept: image/webp,image/apng,image/*,*/*;q=0.8
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Connection: keep-alive
Cache-Control: no-cache
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Pragma: no-cache
Date: Wed, 24 Oct 2018 12:13:19 GMT
Server: nginx
X-Edge-Location: q4web-prod-contentcache-us-east-1-i-0270ad7c6457f53bf
X-Cache-status: MISS
X-Frame-Options: DENY
Connection: keep-alive
Content-Type: image/jpeg
Cache-Control: no-cache, no-store
Set-Cookie: bpazaws52gukakzc__ctrl0_ctl48_uccaptcha=VhcjdQnJEefC4K/eOKObdacWh+Vrv0TGgLBMl35jlwyfSMegbqiCTy+ZFnZR31n7qCkYoueUlxUtuGzoGlgD+lnJkyuEBFNZmQj49sBITIqgWjsKh7W5Fk96r2CTtoCokqJoDM7+me8C+KbD+C/aMg==; path=/; HttpOnly
Content-Length: 3913
Expires: -1

GET
S 200 seal.png
s21.q4cdn.com/488056881/files/design/ 3 KB
3 KB 7ms
5ms Image
image/png 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/seal.png
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: b76d727954edecbe53e9841aec69cae8d5acd0d5cec95d80f2791264c729d3f3

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
last-modified: Tue, 08 Nov 2016 10:47:20 GMT
server: keycdn-engine
x-amz-request-id: 74EFACAE40D93D85
x-edge-location: defr
etag: "880c19b35067b32abc440e36f327dd8a"
x-cache: HIT
content-type: image/png
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 3015
x-amz-id-2: lvRiiEKbXQw/ji2zXWHV1qlov07AjklJRly3H0JvxxF/skL9njglzvZrwRpNnsnvqcL1/bPyWJw=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 seal2.png
s21.q4cdn.com/488056881/files/design/ 3 KB
3 KB 7ms
5ms Image
image/png 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/seal2.png
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 6ab85bc152133401e0ad5ca069990f4a76413499820d4ba95a0dadb063bcc8b8

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
last-modified: Tue, 08 Nov 2016 10:47:21 GMT
server: keycdn-engine
x-amz-request-id: 8CD7C94B537A1B7D
x-edge-location: defr
etag: "be19bc645a5d70db58e4317fb1f7f791"
x-cache: HIT
content-type: image/png
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 3091
x-amz-id-2: 4Il+iOThbBOlPahz47l816JdqRsT7qmD+dCNacNbrG/8qVNIBkESExRaEQlbmTMLBrAvdVxnS0w=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 facebook.jpg
s21.q4cdn.com/488056881/files/design/ 2 KB
2 KB 7ms
6ms Image
image/jpeg 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/facebook.jpg
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 7a2be6ddfe52bc081c15143a5e6739ecd738f38693d90d1ccaa88658c944f085

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
last-modified: Tue, 08 Nov 2016 10:24:32 GMT
server: keycdn-engine
x-amz-request-id: 91A0FF4B49CEE985
x-edge-location: defr
etag: "c0149ddfcca1fbce358812affe120787"
x-cache: HIT
content-type: image/jpeg
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 1684
x-amz-id-2: ZzvkGVfZopAVejAgGsn9f8eS8LS/H+WPjaiO9XILqpuTm2Rt/ahdTL6IQjqnQ+fVtiHO3txhZyY=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 twitter.jpg
s21.q4cdn.com/488056881/files/design/ 2 KB
2 KB 7ms
6ms Image
image/jpeg 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/twitter.jpg
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: e7e2fe588d3ce9fc11a6c5b7341d89f469dbdf076c4c08abc471afb0cb2b4e7e

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
last-modified: Tue, 08 Nov 2016 10:24:32 GMT
server: keycdn-engine
x-amz-request-id: BB191ACDC72254CC
x-edge-location: defr
etag: "387094136ffa421bbb6a0bbeb347ef98"
x-cache: HIT
content-type: image/jpeg
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 1786
x-amz-id-2: xl1qoafrAUMkIOBbEFOSWoDf8Qdf6Y1quZra6m3h4abDOH0VEGuvc7JeHGu0pzwjkfLX9n4RbWI=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 linkedin.jpg
s21.q4cdn.com/488056881/files/design/ 2 KB
2 KB 7ms
6ms Image
image/jpeg 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/linkedin.jpg
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 3de1385de0b5110f71bfd556720078b777982242eba5715c43a3e0181ef3ed67

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
last-modified: Tue, 08 Nov 2016 10:24:32 GMT
server: keycdn-engine
x-amz-request-id: E518594BB5F5F997
x-edge-location: defr
etag: "8fd5e353df9d203a62c61d07cc985343"
x-cache: HIT
content-type: image/jpeg
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 1780
x-amz-id-2: PTXTh0Lxw3oxLUN8PrlLsm17ewTwbIgnDwR7AlZlAAPd5Vmr84gpM5f4wDcgUUJswgC1pV/nY0A=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
H/1.1 200
OK anti-csrf.js Show response
investors.merck.com/js/ 2 KB
3 KB 516ms
123ms Script
application/javascript 69.172.200.241
Dosarrest Interne...

General

Check archive.org

Show headers Download Go to

Full URL

https://investors.merck.com/js/anti-csrf.js

Requested by

Protocol

HTTP/1.1

Security

TLS 1.2, ECDHE_RSA, AES_256_GCM

Server

69.172.200.241 New York, United States, ASN19324 (DOSARREST - Dosarrest Internet Security LTD, US),

Reverse DNS

Software

nginx /

Resource Hash

1187183d18476f0d3e89888f9fae2873e5e910ac3540884e544c5095191b0711

Security Headers

Name	Value
Strict-Transport-Security	max-age=3600

Request headers

Pragma: no-cache
Accept-Encoding: gzip, deflate
Host: investors.merck.com
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Accept: */*
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Connection: keep-alive
Cache-Control: no-cache
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:18 GMT
Last-Modified: Fri, 19 Oct 2018 18:27:42 GMT
Server: nginx
X-Edge-Location: q4web-prod-contentcache-us-east-1-i-067b80e2a3d0b9f5c
ETag: 3f5d51d371a0de9873862ab8c6465bc4
X-Cache-status: REVALIDATED
Strict-Transport-Security: max-age=3600
Content-Type: application/javascript
Cache-Control: public, max-age=10
Connection: keep-alive
Accept-Ranges: bytes
Content-Length: 2281

GET
S 200 print.css
s21.q4cdn.com/488056881/files/css/ 67 B
421 B 8ms
7ms Stylesheet
text/css 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/css/print.css
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 754186856002687df6fd73b82795852e0fbf3292ce6f63094dc3fef3fd464e25

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:18 GMT
last-modified: Wed, 01 Mar 2017 07:23:20 GMT
server: keycdn-engine
x-amz-request-id: 5B9EAAAB6A65B6D8
x-edge-location: defr
etag: "0ecddb0435486622271edaec94ce3a25"
x-cache: HIT
content-type: text/css
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 67
x-amz-id-2: dbbeKS4OrnXOIiGJajXGW1mDcqaBVUuHoHKWWHXKjYK+Zb0Cr/KSoSWduRGozt2Xjl19aUVDers=
expires: Wed, 24 Oct 2018 13:13:18 GMT

GET
S 200 53fb9c60-2054-4c31-9283-5562244b4935.woff2
s21.q4cdn.com/488056881/files/fonts/2017/ 17 KB
18 KB 63ms
10ms Font
application/octet-stream 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/fonts/2017/53fb9c60-2054-4c31-9283-5562244b4935.woff2
Requested by: Host: s21.q4cdn.com
URL: https://s21.q4cdn.com/488056881/files/js/q4.core.js
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 0e4ff26e5ba41cc041ae8d5b66cfca10625d83bcf5cd6fd9db40028d0fcbd19f

Request headers

User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Referer: https://s21.q4cdn.com/488056881/files/css/client.css?v=23851
Origin: https://investors.merck.com

Response headers

date: Wed, 24 Oct 2018 12:13:19 GMT
last-modified: Tue, 18 Apr 2017 13:52:32 GMT
server: keycdn-engine
x-amz-request-id: F5B6A8905428F147
x-edge-location: defr
etag: "3b327ceb8be5f3eaa2bec0e75242c148"
x-cache: HIT
content-type: application/octet-stream
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 17708
x-amz-id-2: U505lkw6Ug3PH4e8V00J24yGT/gZ3h6LFjWFkikYKw/srQhpo8BLSdZmeA10X75T6IDEaUImeuA=
expires: Wed, 24 Oct 2018 13:13:19 GMT

GET
S 200 analytics.js Show response
www.google-analytics.com/ 42 KB
17 KB 8ms
7ms Script
text/javascript 2a00:1450:4001:819::200e
Google LLC

General

Check archive.org

Show headers Download Go to

Full URL

https://www.google-analytics.com/analytics.js

Requested by

Protocol

SPDY

Security

TLS 1.2, ECDHE_RSA, AES_128_GCM

Server

2a00:1450:4001:819::200e , Ireland, ASN15169 (GOOGLE - Google LLC, US),

Reverse DNS

Software

Golfe2 /

Resource Hash

8cb05b675fe6419a9e91eb587c60902c7ed1cb6c42b8cff8ce404ef89f635cde

Security Headers

Name	Value
Strict-Transport-Security	max-age=10886400; includeSubDomains; preload
X-Content-Type-Options	nosniff

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

strict-transport-security: max-age=10886400; includeSubDomains; preload
content-encoding: gzip
x-content-type-options: nosniff
last-modified: Thu, 11 Oct 2018 19:41:26 GMT
server: Golfe2
age: 6655
date: Wed, 24 Oct 2018 10:22:23 GMT
vary: Accept-Encoding
content-type: text/javascript
status: 200
cache-control: public, max-age=7200
timing-allow-origin: *
alt-svc: quic=":443"; ma=2592000; v="44,43,39,35"
content-length: 17301
expires: Wed, 24 Oct 2018 12:22:23 GMT

GET
S 200 print2.css
s21.q4cdn.com/488056881/files/css/ 0
345 B 246ms
245ms Stylesheet
text/css 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/css/print2.css
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:19 GMT
last-modified: Wed, 01 Mar 2017 07:23:20 GMT
server: keycdn-engine
x-amz-request-id: 023B9A493BFC9224
x-edge-location: defr
etag: "d41d8cd98f00b204e9800998ecf8427e"
x-cache: MISS
content-type: text/css
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 0
x-amz-id-2: Ujd/NbmEnIDYY1B9qgGS/Ji4Mt0+9XtXBlKlJ2+pPQtEEg7LnPDC02u/RnwceIJYFrUwbWXB7LA=
expires: Wed, 24 Oct 2018 13:13:19 GMT

GET
S 200 collect
www.google-analytics.com/r/ 35 B
111 B 14ms
14ms Image
image/gif 2a00:1450:4001:819::200e
Google LLC

General

Check archive.org

Show headers Download Go to Show image

Full URL

https://www.google-analytics.com/r/collect?v=1&_v=j71&aip=1&a=1067454281&t=pageview&_s=1&dl=https%3A%2F%2Finvestors.merck.com%2Fnews%2Fpress-release-details%2F2018%2FMercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer%2Fdefault.aspx&dp=%2Fnews%2Fpress-release-details%2F2018%2FMercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer%2Fdefault.aspx&ul=en-us&de=UTF-8&dt=Merck%20%26%20Co.%2C%20Inc.%20-%20Merck%E2%80%99s%20KEYTRUDA%20(pembrolizumab)%20Significantly%20Improved%20Overall%20Survival%20Compared%20to%20Standard%20of%20Care%2C%20as%20Monotherapy%20and%20in%20Combination%20with%20Chemotherapy%2C%20as%20First-Line%20Treatment%20for%20Patients%20with%20Recurrent%20or%20Metastatic%20Head%20and%20Neck%20Cancer&sd=24-bit&sr=1600x1200&vp=1600x1200&je=0&_u=YEBAAEAB~&jid=299158174&gjid=131259098&cid=1818600767.1540383199&tid=UA-75620129-1&_gid=1960123562.1540383199&_r=1&z=445405914

Requested by

Protocol

SPDY

Security

TLS 1.2, ECDHE_RSA, AES_128_GCM

Server

2a00:1450:4001:819::200e , Ireland, ASN15169 (GOOGLE - Google LLC, US),

Reverse DNS

Software

Golfe2 /

Resource Hash

8337212354871836e6763a41e615916c89bac5b3f1f0adf60ba43c7c806e1015

Security Headers

Name	Value
X-Content-Type-Options	nosniff

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

pragma: no-cache
date: Wed, 24 Oct 2018 12:13:19 GMT
x-content-type-options: nosniff
last-modified: Sun, 17 May 1998 03:00:00 GMT
server: Golfe2
status: 200
content-type: image/gif
access-control-allow-origin: *
cache-control: no-cache, no-store, must-revalidate
alt-svc: quic=":443"; ma=2592000; v="44,43,39,35"
content-length: 35
expires: Fri, 01 Jan 1990 00:00:00 GMT

GET
S 200 Invention_W_Rg.woff2
s21.q4cdn.com/488056881/files/fonts/2018/Invention/ 21 KB
22 KB 13ms
11ms Font
application/octet-stream 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/fonts/2018/Invention/Invention_W_Rg.woff2
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 1856f94f08997a2e932cf200bc6d29a46fee7fc71df19ae9b577548b5e163616

Request headers

User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Referer: https://s21.q4cdn.com/488056881/files/css/global.css?v=25127
Origin: https://investors.merck.com

Response headers

date: Wed, 24 Oct 2018 12:13:19 GMT
x-amz-request-id: 510844C359E65465
x-edge-location: defr
x-cache: HIT
status: 200
content-length: 21952
x-amz-id-2: /eX1tnoUv3kW5O8aYDoKeFzwVCqBUwG4E2gTFW/RprVkTL5sAb/kmp7OQu8HWnFreYKq66DmQ5Y=
last-modified: Tue, 11 Sep 2018 23:20:40 GMT
server: keycdn-engine
etag: "f131597b0c0b33b79195671729de4764"
access-control-max-age: 3000
access-control-allow-methods: GET, POST, HEAD
content-type: application/octet-stream
access-control-allow-origin: *
cache-control: max-age=3600
accept-ranges: bytes
expires: Wed, 24 Oct 2018 13:13:19 GMT

GET
S 200 search3.png
s21.q4cdn.com/488056881/files/design/ 2 KB
2 KB 6ms
6ms Image
image/png 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/search3.png
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 4737f6d6cf7e2009ff40c6266acd3d242ba62abc40b408dad59c21c0ca5885fc

Request headers

Referer: https://s21.q4cdn.com/488056881/files/css/global.css?v=25127
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:19 GMT
last-modified: Fri, 14 Apr 2017 01:17:07 GMT
server: keycdn-engine
x-amz-request-id: 4982649902C69176
x-edge-location: defr
etag: "9ddcb67f24067029904ace6f22872119"
x-cache: HIT
content-type: image/png
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 1618
x-amz-id-2: 7pc0prIEcEYUN67fpZdLTlBebQEtG6gmCy3cB2oATZM0D1W7EIOvr7eWddSOBkdBid3G5ZGWxWw=
expires: Wed, 24 Oct 2018 13:13:19 GMT

GET
S 200 Invention_W_Lt.woff2
s21.q4cdn.com/488056881/files/fonts/2018/Invention/ 22 KB
22 KB 6ms
6ms Font
application/octet-stream 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to

Full URL: https://s21.q4cdn.com/488056881/files/fonts/2018/Invention/Invention_W_Lt.woff2
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 17d0dd18f08380e8435ba86d3c7888403e23a286a2aabadd00316916b87652b8

Request headers

User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Referer: https://s21.q4cdn.com/488056881/files/css/global.css?v=25127
Origin: https://investors.merck.com

Response headers

date: Wed, 24 Oct 2018 12:13:19 GMT
x-amz-request-id: C7D4130D5F74945A
x-edge-location: defr
x-cache: HIT
status: 200
content-length: 22112
x-amz-id-2: M0+CY21g9zQQ0uZ0Ed7abMBOAiyEEp9unjeW8YUtAkYe4tJrZQjNZHdLZi0te29TtJc5zo8qIT4=
last-modified: Tue, 11 Sep 2018 23:20:39 GMT
server: keycdn-engine
etag: "33f0302e02d20319314ccf0f6fde3763"
access-control-max-age: 3000
access-control-allow-methods: GET, POST, HEAD
content-type: application/octet-stream
access-control-allow-origin: *
cache-control: max-age=3600
accept-ranges: bytes
expires: Wed, 24 Oct 2018 13:13:19 GMT

GET
H/1.1 200
OK q4icons.woff2
s3.amazonaws.com/icomoon.io/50912/Q4Merck2016RD/ 18 KB
18 KB 414ms
106ms Font
application/font-woff2 52.216.163.69
Amazon.com

General

Check archive.org

Show headers Download Go to

Full URL: https://s3.amazonaws.com/icomoon.io/50912/Q4Merck2016RD/q4icons.woff2?mppei0
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: HTTP/1.1
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 52.216.163.69 Ashburn, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS
Software: AmazonS3 /
Resource Hash: a6b38746917cd174aed3909b8d99734abb4ae99ccc1faf633cb6a2b9403544f9

Request headers

User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Referer: https://s21.q4cdn.com/488056881/files/css/client.css?v=23851
Origin: https://investors.merck.com

Response headers

Date: Wed, 24 Oct 2018 12:13:20 GMT
Last-Modified: Fri, 18 Nov 2016 10:41:35 GMT
Server: AmazonS3
x-amz-request-id: 890DADA8629A80BC
ETag: "df14311c7940f87e938bc7dff201014c"
Vary: Origin, Access-Control-Request-Headers, Access-Control-Request-Method
Access-Control-Allow-Methods: GET
Content-Type: application/font-woff2
Access-Control-Allow-Origin: *
Cache-Control: max-age=31000000
Accept-Ranges: bytes
Content-Length: 17992
x-amz-id-2: yt+TZrW1zfSh5jsF3ctWjI/kThVeQTHfOLzx5UEzVBJiM5xe0aIaFaj75koANYnsaN4nQ092d8A=

GET
H/1.1 200
OK async-buttons.js Show response
ws.sharethis.com/button/ 90 KB
19 KB 7ms
6ms Script
application/javascript 23.43.125.145
AKAMAI-ASN1

General

Check archive.org

Show headers Download Go to

Full URL: https://ws.sharethis.com/button/async-buttons.js
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: HTTP/1.1
Security: TLS 1.2, ECDHE_RSA, AES_256_GCM
Server: 23.43.125.145 Amsterdam, Netherlands, ASN20940 (AKAMAI-ASN1, US),
Reverse DNS: a23-43-125-145.deploy.static.akamaitechnologies.com
Software: nginx/1.12.2 /
Resource Hash: 7dc72c99cab280cec4866890ccabfab6c7118d85022773f170575d684963e983

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:19 GMT
Content-Encoding: gzip
Server: nginx/1.12.2
ETag: W/"5b96ef6a-1686e"
Vary: Accept-Encoding
Content-Type: application/javascript
Cache-Control: max-age=55377
Connection: keep-alive
Content-Length: 19071
Expires: Thu, 25 Oct 2018 03:36:16 GMT

GET
S 200 banner-test.jpg
s21.q4cdn.com/488056881/files/design/slider/ 112 KB
113 KB 8ms
8ms Image
image/jpeg 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/slider/banner-test.jpg
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: a60d0a1b939ebed80a2404d9bb896862b788b934f2e679b807e342c7d6868b8b

Request headers

Referer: https://s21.q4cdn.com/488056881/files/css/global.css?v=25127
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:19 GMT
last-modified: Wed, 14 Dec 2016 10:54:08 GMT
server: keycdn-engine
x-amz-request-id: 9206D90F178E8E79
x-edge-location: defr
etag: "7f29c487aea6ebb9f9bc8831725086d1"
x-cache: HIT
content-type: image/jpeg
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 114852
x-amz-id-2: TibGULiV+H2kWUVJQ8VQAZ/wFTLffzHDN0Q+BUdC9rE6JygNrk7KsK/nu8e2w1ospfbRo3eq078=
expires: Wed, 24 Oct 2018 13:13:19 GMT

GET
S 200 search.png
s21.q4cdn.com/488056881/files/design/ 695 B
1 KB 8ms
8ms Image
image/png 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/search.png
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: f39d31e8216dade5f9440a1b689c7621ca1bc01ed53ff2ee372f2877c9592308

Request headers

Referer: https://s21.q4cdn.com/488056881/files/css/global.css?v=25127
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:19 GMT
last-modified: Mon, 07 Nov 2016 08:55:51 GMT
server: keycdn-engine
x-amz-request-id: 450B6EC7E33A3880
x-edge-location: defr
etag: "dc5c55f19fea9b0a4286d725ede063e9"
x-cache: HIT
content-type: image/png
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 695
x-amz-id-2: utm4kj1l5R5cQT3RdT/7J0oB3leyqxweJ6jVlpy99RaEPosOZL4T8IXu+nqYa9QuPMzaUrY+1ko=
expires: Wed, 24 Oct 2018 13:13:19 GMT

GET
H/1.1 200
OK sidebarv2.js Show response
www.bugherd.com/ 18 B
545 B 444ms
110ms Script
text/javascript 52.207.5.158
Amazon.com

General

Check archive.org

Show headers Download Go to

Full URL

https://www.bugherd.com/sidebarv2.js?apikey=uz0dog65v7bx3wme452olw

Requested by

Protocol

HTTP/1.1

Security

TLS 1.2, ECDHE_RSA, AES_128_GCM

Server

52.207.5.158 Ashburn, United States, ASN14618 (AMAZON-AES - Amazon.com, Inc., US),

Reverse DNS

ec2-52-207-5-158.compute-1.amazonaws.com

Software

Cowboy /

Resource Hash

8dd2e54a09b38c31cfc153f973ede5db1e36de8090b1f8841fd264be362ec0ce

Security Headers

Name	Value
X-Content-Type-Options	nosniff
X-Frame-Options	SAMEORIGIN
X-Xss-Protection	1; mode=block

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

X-Runtime: 0.005806
Date: Wed, 24 Oct 2018 12:13:19 GMT
Content-Encoding: gzip
X-Content-Type-Options: nosniff
Server: Cowboy
Etag: "2edc691cb8f981b62ed28861dd5c4191"
X-Frame-Options: SAMEORIGIN
P3p: CP="NOI ADM DEV COM NAV OUR STP"
Via: 1.1 vegur
Cache-Control: max-age=0, private, must-revalidate
Connection: close
Content-Type: text/javascript; charset=utf-8
Vary: Accept-Encoding
X-Xss-Protection: 1; mode=block
X-Request-Id: a307b7b3-afac-4fbc-8cbd-8fae89ec5a46

GET
H/1.1 200
OK portal.html
c.sharethis.mgr.consensu.org/v1.0/cmp/ Frame 6E0F 0
0 62ms
5ms Document
text/html 2.16.186.243
AKAMAI-ASN1

General

Check archive.org

Show headers Download Go to

Full URL: https://c.sharethis.mgr.consensu.org/v1.0/cmp/portal.html
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: HTTP/1.1
Security: TLS 1.2, ECDHE_ECDSA, AES_256_GCM
Server: 2.16.186.243 , European Union, ASN20940 (AKAMAI-ASN1, US),
Reverse DNS: a2-16-186-243.deploy.static.akamaitechnologies.com
Software: /
Resource Hash

Request headers

Host: c.sharethis.mgr.consensu.org
Connection: keep-alive
Pragma: no-cache
Cache-Control: no-cache
Upgrade-Insecure-Requests: 1
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Accept: text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Accept-Encoding: gzip, deflate
Upgrade-Insecure-Requests: 1
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx

Response headers

Accept-Ranges: bytes
Access-Control-Allow-Headers: Origin, X-Requested-With, Content-Type, Accept
Access-Control-Allow-Methods: DELETE, GET, HEAD, OPTIONS, POST, PUT
Access-Control-Allow-Origin: *
Content-Encoding: gzip
Content-Type: text/html; charset=utf-8
ETag: W/"26b-4977387000"
Last-Modified: Tue, 01 Jan 1980 00:00:00 GMT
Vary: Accept-Encoding
Content-Length: 334
Cache-Control: public, max-age=3600
Date: Wed, 24 Oct 2018 12:13:19 GMT
Connection: keep-alive

GET
S 200 checkbox.png
s21.q4cdn.com/488056881/files/design/ 338 B
695 B 6ms
6ms Image
image/png 185.172.148.132
PROINITY PROINITY

General

Check archive.org

Show headers Download Go to Show image

Full URL: https://s21.q4cdn.com/488056881/files/design/checkbox.png
Requested by: Host: s21.q4cdn.com
URL: https://s21.q4cdn.com/488056881/files/js/q4.core.js
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 185.172.148.132 , Germany, ASN44239 (PROINITY PROINITY, DE),
Reverse DNS
Software: keycdn-engine /
Resource Hash: 04e551520d6b90a2df0b6ab53bbc31872bc3a2b949eb6aa4819626ef51a50a5f

Request headers

Referer: https://s21.q4cdn.com/488056881/files/css/global.css?v=25127
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:19 GMT
last-modified: Tue, 08 Nov 2016 12:25:34 GMT
server: keycdn-engine
x-amz-request-id: 5BA5D03569EF47C6
x-edge-location: defr
etag: "b28b1b8d02a97356e4c6e20eca85b24a"
x-cache: HIT
content-type: image/png
status: 200
cache-control: max-age=3600
accept-ranges: bytes
access-control-allow-origin: *
content-length: 338
x-amz-id-2: Q/O7KQKiXUmjplm86G/yuUeSiLJ5Kz/iZHkNPIQOszEFP39qVzQUFTY883VzQvcBCJ+R6i9V8Ts=
expires: Wed, 24 Oct 2018 13:13:19 GMT

GET
H/1.1

301
Moved Permanently

sc Show response
l.sharethis.com/
Redirect Chain

https://l.sharethis.com/pview?event=pview&version=buttons.js&lang=en&fpc=d13c64-166a5fe4fb6-13f73f01-1&sessionID=1540383199158.59352&hostname=investors.merck.com&location=%2Fnews%2Fpress-release-de...
https://l.sharethis.com/sc?cm=ZGAUr1vQYd8AAAAUG%2FBcAw%3D%3D&uid=true&url=https%3A%2F%2Finvestors.merck.com%2Fnews%2Fpress-release-details%2F2018%2FMercks-KEYTRUDA-pembrolizumab-Significantly-Impro...

0
-1 B

53ms
8ms

XHR
text/html

18.185.192.244
Amazon.com

General

Check archive.org

Show headers Download Go to

Full URL: https://l.sharethis.com/sc?cm=ZGAUr1vQYd8AAAAUG%2FBcAw%3D%3D&uid=true&url=https%3A%2F%2Finvestors.merck.com%2Fnews%2Fpress-release-details%2F2018%2FMercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer%2Fdefault.aspx
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: HTTP/1.1
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 18.185.192.244 Cambridge, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS: ec2-18-185-192-244.eu-central-1.compute.amazonaws.com
Software: /
Resource Hash: e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:19 GMT
Access-Control-Allow-Origin: https://investors.merck.com
Access-Control-Max-Age: 1728000
P3p: policyref="/w3c/p3p.xml", CP="ALL DSP COR CURa ADMa DEVa TAIa PSAa PSDa OUR IND UNI COM NAV INT DEM"
Location: /sc?cm=ZGAUr1vQYd8AAAAUG%2FBcAw%3D%3D&uid=true&url=https%3A%2F%2Finvestors.merck.com%2Fnews%2Fpress-release-details%2F2018%2FMercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer%2Fdefault.aspx
Access-Control-Expose-Headers: stid
Cache-Control: no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials: true
Connection: keep-alive
Content-Type: text/html; charset=utf-8
Access-Control-Allow-Headers: *
Content-Length: 420
Stid: ZGAUr1vQYd8AAAAUG/BcAw==

Redirect headers

Date: Wed, 24 Oct 2018 12:13:19 GMT
Access-Control-Allow-Origin: https://investors.merck.com
Access-Control-Max-Age: 1728000
P3p: policyref="/w3c/p3p.xml", CP="ALL DSP COR CURa ADMa DEVa TAIa PSAa PSDa OUR IND UNI COM NAV INT DEM"
Location: /sc?cm=ZGAUr1vQYd8AAAAUG%2FBcAw%3D%3D&uid=true&url=https%3A%2F%2Finvestors.merck.com%2Fnews%2Fpress-release-details%2F2018%2FMercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer%2Fdefault.aspx
Access-Control-Expose-Headers: stid
Cache-Control: no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials: true
Connection: keep-alive
Content-Type: text/html; charset=utf-8
Access-Control-Allow-Headers: *
Content-Length: 420
Stid: ZGAUr1vQYd8AAAAUG/BcAw==

GET
H/1.1 200
OK buttons-secure.css
ws.sharethis.com/button/css/ 23 KB
4 KB 7ms
7ms Stylesheet
text/css 23.43.125.145
AKAMAI-ASN1

General

Check archive.org

Show headers Download Go to

Full URL: https://ws.sharethis.com/button/css/buttons-secure.css
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: HTTP/1.1
Security: TLS 1.2, ECDHE_RSA, AES_256_GCM
Server: 23.43.125.145 Amsterdam, Netherlands, ASN20940 (AKAMAI-ASN1, US),
Reverse DNS: a23-43-125-145.deploy.static.akamaitechnologies.com
Software: nginx/1.12.2 /
Resource Hash: 95dc1b83a7c030dd13ab3e29df921f10e04208b28734f172ea232854264c3b05

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:19 GMT
Content-Encoding: gzip
Last-Modified: Mon, 10 Sep 2018 22:25:46 GMT
Server: nginx/1.12.2
ETag: W/"5b96ef6a-5a76"
Vary: Accept-Encoding
Content-Type: text/css
Connection: keep-alive
Content-Length: 3851

GET
H/1.1 200
OK sc Show response
l.sharethis.com/ 51 B
477 B 8ms
8ms XHR
text/plain 18.185.192.244
Amazon.com

General

Check archive.org

Show headers Download Go to

Full URL: https://l.sharethis.com/sc?cm=ZGAUr1vQYd8AAAAUG%2FBcAw%3D%3D&uid=true&url=https%3A%2F%2Finvestors.merck.com%2Fnews%2Fpress-release-details%2F2018%2FMercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer%2Fdefault.aspx
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: HTTP/1.1
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 18.185.192.244 Cambridge, United States, ASN16509 (AMAZON-02 - Amazon.com, Inc., US),
Reverse DNS: ec2-18-185-192-244.eu-central-1.compute.amazonaws.com
Software: /
Resource Hash: aa250dfa4d87339b447018af7d04f12f83f22ba4f31533619e2cfa71bc74d734

Request headers

User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Origin: https://investors.merck.com

Response headers

Date: Wed, 24 Oct 2018 12:13:19 GMT
Access-Control-Max-Age: 1728000
Content-Type: text/plain; charset=utf-8
Access-Control-Allow-Origin: https://investors.merck.com
Access-Control-Expose-Headers: stid
Cache-Control: no-cache, no-store, must-revalidate
Access-Control-Allow-Credentials: true
Connection: keep-alive
Stid: ZGAUr1vQYd8AAAAUG/BcAw==
Access-Control-Allow-Headers: *
Content-Length: 51

GET
H/1.1 200
OK p.js Show response
ws.sharethis.com/button/ 3 KB
1 KB 6ms
6ms Script
application/javascript 23.43.125.145
AKAMAI-ASN1

General

Check archive.org

Show headers Download Go to

Full URL: https://ws.sharethis.com/button/p.js
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: HTTP/1.1
Security: TLS 1.2, ECDHE_RSA, AES_256_GCM
Server: 23.43.125.145 Amsterdam, Netherlands, ASN20940 (AKAMAI-ASN1, US),
Reverse DNS: a23-43-125-145.deploy.static.akamaitechnologies.com
Software: nginx/1.12.2 /
Resource Hash: 97875e1cc37494327341a6d4444231a16127ab958907b9e879a87eb99808c7a0

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:19 GMT
Content-Encoding: gzip
Server: nginx/1.12.2
ETag: W/"5b96ef36-bc6"
Vary: Accept-Encoding
Content-Type: application/javascript
Cache-Control: max-age=229403
Connection: keep-alive
Content-Length: 1182
Expires: Sat, 27 Oct 2018 03:56:42 GMT

GET
H/1.1 200
OK t.dhj Show response
t.sharethis.com/1/d/ Frame 3FC7 2 KB
1 KB 54ms
7ms Script
application/javascript 104.111.218.204
Akamai Technologies

General

Check archive.org

Show headers Download Go to

Full URL

https://t.sharethis.com/1/d/t.dhj?rnd=1540383199473&cid=c010&dmn=investors.merck.com

Requested by

Protocol

HTTP/1.1

Security

TLS 1.2, ECDHE_RSA, AES_256_GCM

Server

104.111.218.204 Amsterdam, Netherlands, ASN16625 (AKAMAI-AS - Akamai Technologies, Inc., US),

Reverse DNS

a104-111-218-204.deploy.static.akamaitechnologies.com

Software

Resource Hash

8c4ec873bc5c6a4d4a2767ec2d2a7188d5677713651c8a68ca5c4fbae380e528

Security Headers

Name	Value
X-Content-Type-Options	nosniff

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

Date: Wed, 24 Oct 2018 12:13:19 GMT
Content-Encoding: gzip
X-Content-Type-Options: nosniff
Vary: Accept-Encoding
P3P: policyref="/w3c/p3p.xml", CP="DSP LAW NID OUR DEL SAM BUS UNI PUR COM NAV INT STA PRE LOC OTC"
Cache-Control: private, max-age=3600
Connection: keep-alive
Content-Type: application/javascript
Content-Length: 956
Expires: Wed, 24 Oct 2018 13:13:19 GMT

GET
H/1.1 200
OK t_.htm
t.sharethis.com/a/ Frame 14A9 0
0 7ms
7ms Document
text/html 104.111.218.204
Akamai Technologies

General

Check archive.org

Show headers Download Go to

Full URL: https://t.sharethis.com/a/t_.htm?ver=0.200.7868&cid=c010
Requested by: Host: t.sharethis.com
URL: https://t.sharethis.com/1/d/t.dhj?rnd=1540383199473&cid=c010&dmn=investors.merck.com
Protocol: HTTP/1.1
Security: TLS 1.2, ECDHE_RSA, AES_256_GCM
Server: 104.111.218.204 Amsterdam, Netherlands, ASN16625 (AKAMAI-AS - Akamai Technologies, Inc., US),
Reverse DNS: a104-111-218-204.deploy.static.akamaitechnologies.com
Software: /
Resource Hash

Request headers

Host: t.sharethis.com
Connection: keep-alive
Pragma: no-cache
Cache-Control: no-cache
Upgrade-Insecure-Requests: 1
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Accept: text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Accept-Encoding: gzip, deflate
Cookie: __stid=ZGAUr1vQYd8AAAAUG/BcAw==
Upgrade-Insecure-Requests: 1
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx

Response headers

Vary: Accept-Encoding
Content-Encoding: gzip
Content-Length: 783
Cache-Control: max-age=604800
Expires: Wed, 31 Oct 2018 12:13:19 GMT
Date: Wed, 24 Oct 2018 12:13:19 GMT
Connection: keep-alive
P3P: policyref="/w3c/p3p.xml", CP="DSP LAW NID OUR DEL SAM BUS UNI PUR COM NAV INT STA PRE LOC OTC"
Content-Type: text/html

GET
S 200 nr-spa-1099.min.js Show response
js-agent.newrelic.com/ 33 KB
13 KB 9ms
8ms Script
application/javascript 151.101.2.110
Fastly

General

Check archive.org

Show headers Download Go to

Full URL: https://js-agent.newrelic.com/nr-spa-1099.min.js
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: SPDY
Security: TLS 1.2, ECDHE_RSA, AES_128_GCM
Server: 151.101.2.110 San Francisco, United States, ASN54113 (FASTLY - Fastly, US),
Reverse DNS
Software: AmazonS3 /
Resource Hash: 6be822a61f56042ca816c650cec77f6b988477a3cc1d7836c683d1cf7dd48bc5

Request headers

Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36

Response headers

date: Wed, 24 Oct 2018 12:13:19 GMT
content-encoding: gzip
x-amz-request-id: D1D070027AC18DFC
x-cache: HIT
status: 200
content-length: 12795
x-amz-id-2: r8Lcj02f5Tx8PkM8xXYsTVfOdaBWoG3vydu4TD9Ciiup+3BjPaj1N/SO8NOCTVROEw7k2Gv5FmQ=
x-served-by: cache-hhn1544-HHN
last-modified: Tue, 02 Oct 2018 02:58:55 GMT
server: AmazonS3
x-timer: S1540383200.699239,VS0,VE0
etag: "b5311dcfed22ad3dedbe1a711ede13d8"
vary: Accept-Encoding
content-type: application/javascript
via: 1.1 varnish
cache-control: public, max-age=7200, stale-if-error=604800
accept-ranges: bytes
x-cache-hits: 8234

GET 4b6f7f959c
bam.nr-data.net/1/ 0
0

GET
H/1.1 200
OK index.html
ws.sharethis.com/secure5x/ Frame 0DB5 0
0 7ms
6ms Document
text/html 23.43.125.145
AKAMAI-ASN1

General

Check archive.org

Show headers Download Go to

Full URL: https://ws.sharethis.com/secure5x/index.html
Requested by: Host: investors.merck.com
URL: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Protocol: HTTP/1.1
Security: TLS 1.2, ECDHE_RSA, AES_256_GCM
Server: 23.43.125.145 Amsterdam, Netherlands, ASN20940 (AKAMAI-ASN1, US),
Reverse DNS: a23-43-125-145.deploy.static.akamaitechnologies.com
Software: nginx/1.12.2 /
Resource Hash

Request headers

Host: ws.sharethis.com
Connection: keep-alive
Pragma: no-cache
Cache-Control: no-cache
Upgrade-Insecure-Requests: 1
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Accept: text/html,application/xhtml+xml,application/xml;q=0.9,image/webp,image/apng,*/*;q=0.8
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx
Accept-Encoding: gzip, deflate
Cookie: __stid=ZGAUr1vQYd8AAAAUG/BcAw==
Upgrade-Insecure-Requests: 1
User-Agent: Mozilla/5.0 (Macintosh; Intel Mac OS X 10_13_5) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/67.0.3396.87 Safari/537.36
Referer: https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx

Response headers

Content-Encoding: gzip
Content-Type: text/html
ETag: W/"5b96ef6a-3984"
Last-Modified: Mon, 10 Sep 2018 22:25:46 GMT
Server: nginx/1.12.2
Vary: Accept-Encoding
Content-Length: 4117
Date: Wed, 24 Oct 2018 12:13:20 GMT
Connection: keep-alive

Failed requests

These URLs were requested, but there was no response received. You will also see them in the list above.

Domain: bam.nr-data.net
URL: https://bam.nr-data.net/1/4b6f7f959c?a=18253659,37897911&v=1099.d27c17c&to=b1xWMUIDWBdWARFYX1YWdTZgTVIBUQMQXURnWEcVSA%3D%3D&rst=1754&ref=https://investors.merck.com/news/press-release-details/2018/Mercks-KEYTRUDA-pembrolizumab-Significantly-Improved-Overall-Survival-Compared-to-Standard-of-Care-as-Monotherapy-and-in-Combination-with-Chemotherapy-as-First-Line-Treatment-for-Patients-with-Recurrent-or-Metastatic-Head-and-Neck-Cancer/default.aspx&ap=835&be=494&fe=1737&dc=1377&tt=844AB2C903476DB9&af=err,xhr,stn,ins,spa&perf=%7B%22timing%22:%7B%22of%22:1540383197956,%22n%22:0,%22f%22:0,%22dn%22:1,%22dne%22:61,%22c%22:61,%22s%22:88,%22ce%22:280,%22rq%22:281,%22rp%22:486,%22rpe%22:565,%22dl%22:488,%22di%22:1377,%22ds%22:1377,%22de%22:1441,%22dc%22:1737,%22l%22:1737,%22le%22:1741%7D,%22navigation%22:%7B%7D%7D&jsonp=NREUM.setToken

Verdicts & Comments Add Verdict or Comment

173 JavaScript Global Variables

These are the non-standard "global" variables defined on the window object. These can be helpful in identifying possible client-side frameworks and code.

7 Cookies

Cookies are little pieces of information stored in the browser of a user. Whenever a user visits the site again, he will also send his cookie values, thus allowing the website to re-identify him even if he changed locations. This is how permanent logins work.

Domain/Path	Expires	Name / Value
.t.sharethis.com/	1970-01-18 20:03:07	Name: pxcelPage_c010 Value: 0_13_1540383199572
.sharethis.com/	1970-01-19 04:38:39	Name: __stid Value: ZGAUr1vQYd8AAAAUG/BcAw==
.merck.com/	1970-01-19 02:25:26	Name: __unam Value: d13c64-166a5fe4fb6-13f73f01-2
investors.merck.com/	1969-12-31 23:59:59	Name: bpazaws52gukakzc__ctrl0_ctl48_uccaptcha Value: VhcjdQnJEefC4K/eOKObdacWh+Vrv0TGgLBMl35jlwyfSMegbqiCTy+ZFnZR31n7qCkYoueUlxUtuGzoGlgD+lnJkyuEBFNZmQj49sBITIqgWjsKh7W5Fk96r2CTtoCokqJoDM7+me8C+KbD+C/aMg==
.merck.com/	1970-01-19 13:24:15	Name: _ga Value: GA1.2.1818600767.1540383199
.merck.com/	1970-01-18 19:53:03	Name: _gat Value: 1
.merck.com/	1970-01-18 19:54:29	Name: _gid Value: GA1.2.1960123562.1540383199

Security Headers

This page lists any security headers set by the main page. If you want to understand what these mean and how to use them, head on over to this page

Header	Value
Strict-Transport-Security	max-age=3600

Indicators

This is a term in the security industry to describe indicators such as IPs, Domains, Hashes, etc. This does not imply that any of these indicate malicious activity.

bam.nr-data.net
c.sharethis.mgr.consensu.org
cts.businesswire.com
fonts.googleapis.com
investors.merck.com
js-agent.newrelic.com
l.sharethis.com
q4widgets.q4web.com
s21.q4cdn.com
s3.amazonaws.com
t.sharethis.com
ws.sharethis.com
www.bugherd.com
www.businesswire.com
www.google-analytics.com
bam.nr-data.net
104.111.218.204
146.20.91.139
151.101.2.110
18.185.192.244
185.172.148.132
2.16.186.243
204.8.173.180
23.43.125.145
23.8.12.53
2a00:1450:4001:819::200a
2a00:1450:4001:819::200e
52.207.5.158
52.216.163.69
69.172.200.241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investors.merck.com Open in urlscan Pro 69.172.200.241 Public Scan

Summary

urlscan.io Verdict: No classification

Domain & IP information

Screenshot Live screenshot Full Image

Detected technologies

Page Statistics

52 Requests

98 %HTTPS

14 %IPv6

12 Domains

15 Subdomains

14 IPs

5 Countries

715 kBTransfer

1546 kBSize

7 Cookies

139 Outgoing links

Redirected requests

52 HTTP transactions Everything HTML Script AJAX CSS Image Expand all 0 data transactions

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Redirect headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

Response headers

Request headers

investors.merck.com Open in urlscan Pro
69.172.200.241 Public Scan

Screenshot
Live screenshot

Full Image

52
Requests

98 %
HTTPS

14 %
IPv6

12
Domains

15
Subdomains

14
IPs

5
Countries

715 kB
Transfer

1546 kB
Size

7
Cookies

52 HTTP transactions
0 data transactions